houston tirzepatide Medical Weight Loss To keep pounds off, patients

Discover strategies to manage this side effect from weight loss treatments.

Leading Players in the GLP-1 Market Novo Nordisk 38.72% Ozempic Wegovy Rybelsus Eli Lilly 28.41% Mounjaro Zepbound Sanofi 8.76% 4 AstraZeneca 6.62% 5 GSK 4.95% 6 Regeneron 3.27% 7 Pfizer 2.61% 8 Amgen 1.98% 9 Sun Pharma 1.52% Boehringer Ingelheim 1.24% Together, Novo Nordisk and Eli Lilly account for more than 67% of the market, highlighting the intense competition between the two companies that currently lead the obesity and diabetes treatment revolution

Systematic evaluation of glucose control, body mass index, blood pressure, insulin secretion and insulin resistance is leveraged to identify patients who are likely to receive the greatest metabolic benefit from common antidiabetic drugs.

Injection site reactions are common with peptides

Once you reach your weight loss goal on semaglutide, the real challenge begins: keeping the weight off